--- type: "firecrawl-provider" description: "The EU Clinical Trials Information System (CTIS), the European Medicines Agency's public register of every clinical trial authorised under the EU Clinical Trials Regulation (about 12,700 trials, including those transitioned from EudraCT), through its public JSON API: search by text, condition, medicine, sponsor, EU/EEA country, phase, status, decision or start date, rare disease, orphan designation and results, and read one full trial record by EU CT number, CTIS URL or a linked NCT, EudraCT, ISRCTN or WHO UTN number, with per-country decisions, statuses and sites, products and active substances, endpoints, eligibility, safety events, corrective measures, modifications and results. Every result carries EMA's reuse terms." use_when: "The EU Clinical Trials Information System (CTIS), the European Medicines Agency's public register of every clinical trial authorised under the EU Clinical Trials Regulation (about 12,700 trials, including those transitioned from EudraCT), through its public JSON API: search by text, condition, medicine, sponsor, EU/EEA country, phase, status, decision or start date, rare disease, orphan designation and results, and read one full trial record by EU CT number, CTIS URL or a linked NCT, EudraCT, ISRCTN or WHO UTN number, with per-country decisions, statuses and sites, products and active substances, endpoints, eligibility, safety events, corrective measures, modifications and results. Every result carries EMA's reuse terms." categories: "Life sciences" capabilities: 2 credits_per_call: 5 --- # EU Clinical Trials (CTIS) on Firecrawl Alexandria The EU Clinical Trials Information System (CTIS), the European Medicines Agency's public register of every clinical trial authorised under the EU Clinical Trials Regulation (about 12,700 trials, including those transitioned from EudraCT), through its public JSON API: search by text, condition, medicine, sponsor, EU/EEA country, phase, status, decision or start date, rare disease, orphan designation and results, and read one full trial record by EU CT number, CTIS URL or a linked NCT, EudraCT, ISRCTN or WHO UTN number, with per-country decisions, statuses and sites, products and active substances, endpoints, eligibility, safety events, corrective measures, modifications and results. Every result carries EMA's reuse terms. - Categories: Life sciences - Category index: [Life sciences category](https://firecrawl.dev/alexandria/agents/categories/life-sciences) - Provider key: `euclinicaltrials-eu` - Access: Firecrawl credits - Cost: 5 credits per call ## More - [Human guide](https://firecrawl.dev/app/alexandria/euclinicaltrials-eu) - [OpenAPI spec](https://firecrawl.dev/alexandria/agents/providers/euclinicaltrials-eu/openapi.json) ## Capabilities - [Search](https://firecrawl.dev/alexandria/agents/providers/euclinicaltrials-eu/clinical-trials/search): Search CTIS (POST /ctis-public-api/search) by words in the record, medical condition, product or active substance, sponsor, EU/EEA country, phase, status, decision-date or EEA start-date range, rare disease, orphan designation and submitted results. Returns one page of trials sorted by authorisation decision date, each with its EU CT number, titles, overall and per-country status, phase, conditions, products, sponsor, key dates and results flag, plus the total and a page token. An empty result is a valid empty page. - [Study](https://firecrawl.dev/alexandria/agents/providers/euclinicaltrials-eu/clinical-trials/study): One full CTIS trial record (GET /ctis-public-api/retrieve/{EU CT number}) by EU CT number, CTIS URL, or another identifier the trial lists (NCT, EudraCT, ISRCTN or WHO UTN). Returns titles, status, phase, conditions, objective, primary and secondary endpoints, eligibility, products with active substances, ATC codes and orphan designations, paediatric plans, sponsors and funders, planned enrolment, every EU/EEA country with its decision, status, dates and sites, countries outside the EEA, trial events and safety notifications (halts, early terminations, urgent safety measures, serious breaches, corrective measures), applications and modifications, and submitted results, with EMA's reuse terms. ## 1. Choose this provider when The EU Clinical Trials Information System (CTIS), the European Medicines Agency's public register of every clinical trial authorised under the EU Clinical Trials Regulation (about 12,700 trials, including those transitioned from EudraCT), through its public JSON API: search by text, condition, medicine, sponsor, EU/EEA country, phase, status, decision or start date, rare disease, orphan designation and results, and read one full trial record by EU CT number, CTIS URL or a linked NCT, EudraCT, ISRCTN or WHO UTN number, with per-country decisions, statuses and sites, products and active substances, endpoints, eligibility, safety events, corrective measures, modifications and results. Every result carries EMA's reuse terms. ## 2. Minimal request Call `POST https://api.firecrawl.dev/v2/scrape` with `{ alexandria: { provider, capability, options } }`. For a batch, send `{ alexandria: [...] }` with up to 10 calls. ```json { "provider": "euclinicaltrials-eu", "capability": "clinical-trials/search", "options": { "condition": "obesity", "page_size": 3, "status": [ "AUTHORISED_RECRUITING", "ONGOING_RECRUITING" ] } } ``` ## 3. Add provider options Use only the options needed for the task: - `condition` (string): Medical condition, matched within the condition field without case, e.g. melanoma. Example: `` - `decided_from` (string): Authorisation decision on or after this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `decided_to` (string): Authorisation decision on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `has_results` (boolean): true keeps trials with results submitted to CTIS, false keeps the rest. Example: `false` - `member_states` (string[]): Trials in any of these EU/EEA countries (ISO 3166-1 alpha-2). Example: `[]` - `orphan_designation` (boolean): true keeps trials of a product with an EU orphan designation. Example: `false` - `page_size` (number): Trials per page. Example: `10` - `page_token` (string): next_page_token from the previous page; send the same inputs again. Example: `` - `phase` (string[]): Any of these phases; integrated phases match both (PHASE2 matches Phase I/II, Phase II and Phase II/III). Example: `[]` - `product` (string): Medicinal product or active substance, brand name or INN, e.g. semaglutide or Keytruda. ATC codes are not matched. Example: `` - `query` (string): Words that must all appear in the trial record, matched as whole words without case, e.g. "cardiac arrest", a drug code, or an NCT, EudraCT or WHO UTN number. Example: `` - `rare_disease` (boolean): true keeps trials on a rare disease, false keeps the rest. Example: `false` - `sort` (string): Order by authorisation decision date. CTIS serves the first 10,000 trials of either order. Example: `newest_decision` - `sponsor` (string): Sponsor organisation, e.g. Novo Nordisk. Example: `` - `started_from` (string): Trial started in the EU/EEA on or after this date, YYYY-MM-DD; trials without a start date are excluded. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `started_to` (string): Trial started in the EU/EEA on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `status` (string[]): Overall trial status is any of these. Recruiting trials are AUTHORISED_RECRUITING (authorised, recruitment not started) and ONGOING_RECRUITING. Example: `[]` ## 4. Request through your preferred interface ### JavaScript ```javascript const result = await firecrawl.scrape({ alexandria: { provider: "euclinicaltrials-eu", capability: "clinical-trials/search", options: { condition: "obesity", page_size: 3, status: [ "AUTHORISED_RECRUITING", "ONGOING_RECRUITING", ], }, }, }); ``` ### Python ```python result = firecrawl.scrape_alexandria({ "provider": "euclinicaltrials-eu", "capability": "clinical-trials/search", "options": { "condition": "obesity", "page_size": 3, "status": [ "AUTHORISED_RECRUITING", "ONGOING_RECRUITING" ] } }) ``` ### cURL ```sh curl https://api.firecrawl.dev/v2/scrape \ -H "Authorization: Bearer $FIRECRAWL_API_KEY" \ -H "Content-Type: application/json" \ -d '{ "alexandria": { "provider": "euclinicaltrials-eu", "capability": "clinical-trials/search", "options": { "condition": "obesity", "page_size": 3, "status": [ "AUTHORISED_RECRUITING", "ONGOING_RECRUITING" ] } } }' ``` ### CLI ```sh firecrawl scrape 'euclinicaltrials-eu/clinical-trials/search' \ --options '{"condition":"obesity","page_size":3,"status":["AUTHORISED_RECRUITING","ONGOING_RECRUITING"]}' ``` ### MCP Call the FCX MCP retrieve tool with this object: ```json { "provider": "euclinicaltrials-eu", "capability": "clinical-trials/search", "options": { "condition": "obesity", "page_size": 3, "status": [ "AUTHORISED_RECRUITING", "ONGOING_RECRUITING" ] } } ``` Ask for only the returned fields needed by the task. ## 5. Full request shape ```json { "provider": "euclinicaltrials-eu", "capability": "clinical-trials/search", "options": { "condition": "obesity", "page_size": 3, "status": [ "AUTHORISED_RECRUITING", "ONGOING_RECRUITING" ] } } ``` ## 6. Response data The response includes `success`, `provider`, `capability`, `creditsCost` and `data`. This example shows the provider payload in `data`: ```json { "api_url": "https://euclinicaltrials.eu/ctis-public-api/search", "license": { "attribution": "Source: EU Clinical Trials Information System (CTIS), European Medicines Agency, https://euclinicaltrials.eu. EMA permits reproduction, including commercial, provided EMA is acknowledged as the source; sponsor-supplied documents are third-party content and are not included.", "name": "EMA legal notice (reuse with acknowledgement)", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "next_page_token": "3_63_b070d059", "observed_at_ms": 1793381608820, "search_criteria": { "medicalCondition": "obesity", "status": [ 3, 4 ] }, "sort": "newest_decision", "studies": [ { "conditions": "Obesity or Overweight, Weight-Related Comorbidity, without Diabetes Mellitus, Type 2", "decision_date": "2026-10-08", "end_date": null, "eu_ct_number": "2025-523379-41-00", "global_end_date": null, "has_results": false, "last_updated_date": "2026-10-12", "member_states": [ { "code": "IT", "decision_date": "2026-10-08", "name": "Italy", "status": "AUTHORISED_RECRUITMENT_PENDING" }, { "code": "CZ", "decision_date": "2026-10-08", "name": "Czechia", "status": "ONGOING_RECRUITING" }, { "code": "DE", "decision_date": "2026-10-08", "name": "Germany", "status": "ONGOING_RECRUITING" }, { "code": "BG", "decision_date": "2026-10-12", "name": "Bulgaria", "status": "ONGOING_RECRUITING" }, { "code": "FR", "decision_date": "2026-10-12", "name": "France", "status": "AUTHORISED_RECRUITING" }, { "code": "PL", "decision_date": "2026-10-09", "name": "Poland", "status": "ONGOING_RECRUITING" } ], "official_title": "A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus", "outside_eea": true, "overall_status": "ONGOING_RECRUITING", "phase": "Therapeutic confirmatory (Phase III)", "phases": [ "PHASE3" ], "planned_enrollment_eea": 825, "products": "Placebo to match AZD6234, AZD6234, AZD6234, AZD6234, AZD6234", "protocol_code": "D8750C00014", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2025-523379-41-00?lang=en", "sponsor": "AstraZeneca AB", "start_date": "2026-10-22", "therapeutic_areas": [ "Diseases [C] - Nutritional and Metabolic Diseases [C18]" ] }, { "conditions": "Obesity or overweight Diabetes Mellitus, Type 2", "decision_date": "2026-10-05", "end_date": null, "eu_ct_number": "2025-524616-11-00", "global_end_date": null, "has_results": false, "last_updated_date": "2026-10-09", "member_states": [ { "code": "ES", "decision_date": "2026-10-09", "name": "Spain", "status": "ONGOING_RECRUITING" }, { "code": "PL", "decision_date": "2026-10-09", "name": "Poland", "status": "ONGOING_RECRUITING" }, { "code": "SK", "decision_date": "2026-10-05", "name": "Slovakia", "status": "ONGOING_RECRUITING" }, { "code": "DE", "decision_date": "2026-10-06", "name": "Germany", "status": "ONGOING_RECRUITING" } ], "official_title": "A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight", "outside_eea": true, "overall_status": "ONGOING_RECRUITING", "phase": "Therapeutic confirmatory (Phase III)", "phases": [ "PHASE3" ], "planned_enrollment_eea": 420, "products": "AZD6234, Placebo to match AZD6234, AZD6234, AZD6234, AZD6234", "protocol_code": "D8750C00012", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2025-524616-11-00?lang=en", "sponsor": "AstraZeneca AB", "start_date": "2026-10-26", "therapeutic_areas": [ "Diseases [C] - Nutritional and Metabolic Diseases [C18]" ] }, { "conditions": "Obesity or Overweight Weight-Related Comorbidity with/without Diabetes Mellitus, Type 2", "decision_date": "2026-09-21", "end_date": null, "eu_ct_number": "2025-523295-23-00", "global_end_date": null, "has_results": false, "last_updated_date": "2026-09-28", "member_states": [ { "code": "SE", "decision_date": "2026-09-21", "name": "Sweden", "status": "ONGOING_RECRUITING" }, { "code": "DK", "decision_date": "2026-09-28", "name": "Denmark", "status": "ONGOING_RECRUITING" } ], "official_title": "A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus", "outside_eea": true, "overall_status": "ONGOING_RECRUITING", "phase": "Therapeutic confirmatory (Phase III)", "phases": [ "PHASE3" ], "planned_enrollment_eea": 125, "products": "AZD6234, Placebo to match AZD6234, AZD6234, AZD6234, AZD6234", "protocol_code": "D8750C00011", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2025-523295-23-00?lang=en", "sponsor": "AstraZeneca AB", "start_date": "2026-10-12", "therapeutic_areas": [ "Diseases [C] - Nutritional and Metabolic Diseases [C18]" ] } ], "total_count": 63 } ``` ## API reference-derived contract The following capability contract is generated from the same normalized Alexandria API reference exposed in the API spec. ### Search - Capability: `clinical-trials/search` - Description: Search CTIS (POST /ctis-public-api/search) by words in the record, medical condition, product or active substance, sponsor, EU/EEA country, phase, status, decision-date or EEA start-date range, rare disease, orphan designation and submitted results. Returns one page of trials sorted by authorisation decision date, each with its EU CT number, titles, overall and per-country status, phase, conditions, products, sponsor, key dates and results flag, plus the total and a page token. An empty result is a valid empty page. - Instructions: Find EU trials on a condition or medicine, from a sponsor, in an EU/EEA country, with a status or decided in a period, before calling study for the full record. For a known EU CT number, CTIS link, or NCT/EudraCT/ISRCTN number, call study directly. - Cost: 5 credits per call - Capability file: [Search](https://firecrawl.dev/alexandria/agents/providers/euclinicaltrials-eu/clinical-trials/search) Accepted options: - `condition` (string): Medical condition, matched within the condition field without case, e.g. melanoma. Example: `` - `decided_from` (string): Authorisation decision on or after this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `decided_to` (string): Authorisation decision on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `has_results` (boolean): true keeps trials with results submitted to CTIS, false keeps the rest. Example: `false` - `member_states` (string[]): Trials in any of these EU/EEA countries (ISO 3166-1 alpha-2). Example: `[]` - `orphan_designation` (boolean): true keeps trials of a product with an EU orphan designation. Example: `false` - `page_size` (number): Trials per page. Example: `10` - `page_token` (string): next_page_token from the previous page; send the same inputs again. Example: `` - `phase` (string[]): Any of these phases; integrated phases match both (PHASE2 matches Phase I/II, Phase II and Phase II/III). Example: `[]` - `product` (string): Medicinal product or active substance, brand name or INN, e.g. semaglutide or Keytruda. ATC codes are not matched. Example: `` - `query` (string): Words that must all appear in the trial record, matched as whole words without case, e.g. "cardiac arrest", a drug code, or an NCT, EudraCT or WHO UTN number. Example: `` - `rare_disease` (boolean): true keeps trials on a rare disease, false keeps the rest. Example: `false` - `sort` (string): Order by authorisation decision date. CTIS serves the first 10,000 trials of either order. Example: `newest_decision` - `sponsor` (string): Sponsor organisation, e.g. Novo Nordisk. Example: `` - `started_from` (string): Trial started in the EU/EEA on or after this date, YYYY-MM-DD; trials without a start date are excluded. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `started_to` (string): Trial started in the EU/EEA on or before this date, YYYY-MM-DD. Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `status` (string[]): Overall trial status is any of these. Recruiting trials are AUTHORISED_RECRUITING (authorised, recruitment not started) and ONGOING_RECRUITING. Example: `[]` Response schema example: ```json { "api_url": "https://euclinicaltrials.eu/ctis-public-api/search", "license": { "attribution": "Source: EU Clinical Trials Information System (CTIS), European Medicines Agency, https://euclinicaltrials.eu. EMA permits reproduction, including commercial, provided EMA is acknowledged as the source; sponsor-supplied documents are third-party content and are not included.", "name": "EMA legal notice (reuse with acknowledgement)", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "next_page_token": "3_63_b070d059", "observed_at_ms": 1793381608820, "search_criteria": { "medicalCondition": "obesity", "status": [ 3, 4 ] }, "sort": "newest_decision", "studies": [ { "conditions": "Obesity or Overweight, Weight-Related Comorbidity, without Diabetes Mellitus, Type 2", "decision_date": "2026-10-08", "end_date": null, "eu_ct_number": "2025-523379-41-00", "global_end_date": null, "has_results": false, "last_updated_date": "2026-10-12", "member_states": [ { "code": "IT", "decision_date": "2026-10-08", "name": "Italy", "status": "AUTHORISED_RECRUITMENT_PENDING" }, { "code": "CZ", "decision_date": "2026-10-08", "name": "Czechia", "status": "ONGOING_RECRUITING" }, { "code": "DE", "decision_date": "2026-10-08", "name": "Germany", "status": "ONGOING_RECRUITING" }, { "code": "BG", "decision_date": "2026-10-12", "name": "Bulgaria", "status": "ONGOING_RECRUITING" }, { "code": "FR", "decision_date": "2026-10-12", "name": "France", "status": "AUTHORISED_RECRUITING" }, { "code": "PL", "decision_date": "2026-10-09", "name": "Poland", "status": "ONGOING_RECRUITING" } ], "official_title": "A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus", "outside_eea": true, "overall_status": "ONGOING_RECRUITING", "phase": "Therapeutic confirmatory (Phase III)", "phases": [ "PHASE3" ], "planned_enrollment_eea": 825, "products": "Placebo to match AZD6234, AZD6234, AZD6234, AZD6234, AZD6234", "protocol_code": "D8750C00014", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2025-523379-41-00?lang=en", "sponsor": "AstraZeneca AB", "start_date": "2026-10-22", "therapeutic_areas": [ "Diseases [C] - Nutritional and Metabolic Diseases [C18]" ] }, { "conditions": "Obesity or overweight Diabetes Mellitus, Type 2", "decision_date": "2026-10-05", "end_date": null, "eu_ct_number": "2025-524616-11-00", "global_end_date": null, "has_results": false, "last_updated_date": "2026-10-09", "member_states": [ { "code": "ES", "decision_date": "2026-10-09", "name": "Spain", "status": "ONGOING_RECRUITING" }, { "code": "PL", "decision_date": "2026-10-09", "name": "Poland", "status": "ONGOING_RECRUITING" }, { "code": "SK", "decision_date": "2026-10-05", "name": "Slovakia", "status": "ONGOING_RECRUITING" }, { "code": "DE", "decision_date": "2026-10-06", "name": "Germany", "status": "ONGOING_RECRUITING" } ], "official_title": "A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight", "outside_eea": true, "overall_status": "ONGOING_RECRUITING", "phase": "Therapeutic confirmatory (Phase III)", "phases": [ "PHASE3" ], "planned_enrollment_eea": 420, "products": "AZD6234, Placebo to match AZD6234, AZD6234, AZD6234, AZD6234", "protocol_code": "D8750C00012", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2025-524616-11-00?lang=en", "sponsor": "AstraZeneca AB", "start_date": "2026-10-26", "therapeutic_areas": [ "Diseases [C] - Nutritional and Metabolic Diseases [C18]" ] }, { "conditions": "Obesity or Overweight Weight-Related Comorbidity with/without Diabetes Mellitus, Type 2", "decision_date": "2026-09-21", "end_date": null, "eu_ct_number": "2025-523295-23-00", "global_end_date": null, "has_results": false, "last_updated_date": "2026-09-28", "member_states": [ { "code": "SE", "decision_date": "2026-09-21", "name": "Sweden", "status": "ONGOING_RECRUITING" }, { "code": "DK", "decision_date": "2026-09-28", "name": "Denmark", "status": "ONGOING_RECRUITING" } ], "official_title": "A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus", "outside_eea": true, "overall_status": "ONGOING_RECRUITING", "phase": "Therapeutic confirmatory (Phase III)", "phases": [ "PHASE3" ], "planned_enrollment_eea": 125, "products": "AZD6234, Placebo to match AZD6234, AZD6234, AZD6234, AZD6234", "protocol_code": "D8750C00011", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2025-523295-23-00?lang=en", "sponsor": "AstraZeneca AB", "start_date": "2026-10-12", "therapeutic_areas": [ "Diseases [C] - Nutritional and Metabolic Diseases [C18]" ] } ], "total_count": 63 } ``` ### Study - Capability: `clinical-trials/study` - Description: One full CTIS trial record (GET /ctis-public-api/retrieve/{EU CT number}) by EU CT number, CTIS URL, or another identifier the trial lists (NCT, EudraCT, ISRCTN or WHO UTN). Returns titles, status, phase, conditions, objective, primary and secondary endpoints, eligibility, products with active substances, ATC codes and orphan designations, paediatric plans, sponsors and funders, planned enrolment, every EU/EEA country with its decision, status, dates and sites, countries outside the EEA, trial events and safety notifications (halts, early terminations, urgent safety measures, serious breaches, corrective measures), applications and modifications, and submitted results, with EMA's reuse terms. - Instructions: You have an EU CT number (from search or a pasted euclinicaltrials.eu link) or a trial's NCT, EudraCT, ISRCTN or WHO UTN number and need where it runs in Europe, its status per country, eligibility, products, safety events or results. - Cost: 5 credits per call - Capability file: [Study](https://firecrawl.dev/alexandria/agents/providers/euclinicaltrials-eu/clinical-trials/study) Accepted options: - `eu_ct_number` (string): EU CT number, e.g. 2022-500744-38-00. Pass exactly one of eu_ct_number, url or secondary_id. Example: `` - `secondary_id` (string): An NCT, EudraCT, ISRCTN or WHO UTN number the trial lists; matched exactly against the record. Fails with ambiguous_secondary_id when several trials list it. Example: `` - `url` (string): A euclinicaltrials.eu trial link: the portal's ?EUCT= link, /ctis-public/view/{EU CT number}, or the API record URL. Example: `` Response schema example: ```json { "api_url": "https://euclinicaltrials.eu/ctis-public-api/retrieve/2022-500744-38-00", "applications": [ { "decision_date": "2022-07-04", "status": "AUTHORISED", "submitted_date": "2022-05-08", "type": "INITIAL" }, { "decision_date": "2023-01-22", "status": "AUTHORISED", "submitted_date": "2022-10-10", "type": "SUBSTANTIAL_MODIFICATION" }, { "decision_date": "2023-09-29", "status": "AUTHORISED", "submitted_date": "2023-08-14", "type": "SUBSTANTIAL_MODIFICATION" }, { "decision_date": "2023-11-20", "status": "NOT_AUTHORISED", "submitted_date": "2023-10-03", "type": "SUBSTANTIAL_MODIFICATION" } ], "brief_title": "Type of Access to the Blood Circulation During Cardiac Arrest Outside the Hospital", "conditions": [ { "name": "Out-of-hospital cardiac arrest (OHCA)", "rare_disease": false } ], "decision_date": "2022-07-04", "eligibility": { "age_groups": [ "18-64", "65+" ], "exclusion_criteria": [ "Blunt trauma, penetrating trauma, or burn injuries as suspected cause of the cardiac arrest", "Prior enrollment in the trial", "Intravenous or intraosseous vascular access already in place and working at the time of randomization" ], "inclusion_criteria": [ "Out-of-hospital cardiac arrest", "Age ≥ 18 years", "Indication for intravenous or intraosseous vascular access during cardiac arrest" ], "population_groups": [ "Patients" ], "sexes": [ "FEMALE", "MALE" ] }, "end_date": "2025-05-05", "estimated_end_date": "2024-03-01", "estimated_global_end_date": null, "estimated_recruitment_start_date": "2022-05-18", "eu_ct_number": "2022-500744-38-00", "eudract_number": "2021-005922-82", "events": [ { "date": "2022-03-01", "detail": null, "member_states": [ "DK" ], "type": "START_OF_TRIAL" }, { "date": "2022-03-02", "detail": null, "member_states": [ "DK" ], "type": "START_OF_RECRUITMENT" }, { "date": "2024-05-13", "detail": null, "member_states": [ "DK" ], "type": "END_OF_RECRUITMENT" }, { "date": "2025-05-05", "detail": null, "member_states": [ "DK" ], "type": "END_OF_TRIAL" } ], "funders": [ "TrygFonden", "Aarhus University", "Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond through The Danish Heart Foundation", "the Independent Research Fund Denmark", "Novo Nordisk Foundation" ], "global_end_date": null, "has_results": true, "license": { "attribution": "Source: EU Clinical Trials Information System (CTIS), European Medicines Agency, https://euclinicaltrials.eu. EMA permits reproduction, including commercial, provided EMA is acknowledged as the source; sponsor-supplied documents are third-party content and are not included.", "name": "EMA legal notice (reuse with acknowledgement)", "url": "https://www.ema.europa.eu/en/about-us/about-website/legal-notice" }, "low_intervention": false, "main_objective": "To determine whether there is a difference in return of spontaneous circulation depending on the type of vascular access (intravenous or intraosseous) placed during out-of-hospital cardiac arrest", "member_states": [ { "code": "DK", "decision": "AUTHORISED_WITH_CONDITIONS", "decision_date": "2022-07-04", "name": "Denmark", "planned_enrollment": 1470, "recruitment_start_date": "2022-03-02", "sites": [ { "city": "Næstved", "organisation": "Præhospitalt Center, Region Sjælland" }, { "city": "Aalborg", "organisation": "Den Praehospitale Virksomhed" }, { "city": "Vejle", "organisation": "Praehospital indsats Region Syddanmark" }, { "city": "Aarhus N", "organisation": "Præhospitalet" }, { "city": "Ballerup", "organisation": "Region Hovedstadens Akutberedskab" } ], "start_date": "2022-03-01", "status": "ENDED" } ], "nct_ids": [ "NCT05205031" ], "observed_at_ms": 1793381612280, "official_title": "Intravenous vs. Intraosseous Vascular Access During Out-of-Hospital Cardiac Arrest – A Randomized Clinical Trial", "outside_eea_countries": [], "overall_status": "ENDED", "paediatric_investigation_plans": [], "phase": "Therapeutic exploratory (Phase II)", "phases": [ "PHASE2" ], "planned_enrollment": { "eea": 1470, "outside_eea": 0, "total": 1470 }, "primary_endpoints": [ "Sustained return of spontaneous circulation (ROSC). ROSC is defined as palpable pulses or other signs of circulation without a need for chest compressions. Sustained ROSC means that the patient withholds ROSC >20 min" ], "products": [ { "active_substances": [ "ADRENALINE TARTRATE PH. EUR." ], "atc_code": "C01CA24", "eu_product_number": "SCP16873011", "marketing_authorisation_number": null, "name": "EPINEPHRINE", "orphan_designation_number": null, "pharmaceutical_form": null, "role": "TEST", "routes": [ "INTRAVENOUS BOLUS USE" ] }, { "active_substances": [], "atc_code": "C01BD01", "eu_product_number": "SCP177718", "marketing_authorisation_number": null, "name": "AMIODARONE", "orphan_designation_number": null, "pharmaceutical_form": null, "role": "TEST", "routes": [ "INTRAVENOUS BOLUS USE" ] } ], "protocol_code": "2.2", "results": [ { "final": true, "procedure_outcome": null, "procedure_outcome_date": null, "procedure_type": null, "submitted_date": "2026-04-28", "type": "SUMMARY" }, { "final": true, "procedure_outcome": null, "procedure_outcome_date": null, "procedure_type": null, "submitted_date": "2026-04-28", "type": "LAYPERSON_SUMMARY" } ], "secondary_endpoints": [ "Key secondary outcomes will include survival as well as neurological outcome at 30 days. Neurological outcome will be assessed with the modified Rankin Scale (mRS); scores 0-6 will be presented as counts and percentages, while the outcome will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6)." ], "secondary_ids": [], "source_updated_at": "2026-04-29", "source_url": "https://euclinicaltrials.eu/ctis-public/view/2022-500744-38-00?lang=en", "sponsors": [ { "commercial": false, "name": "Præhospitalet", "primary": true, "type": "Hospital/Clinic/Other health care facility" } ], "start_date": "2022-03-01", "therapeutic_areas": [ "Diseases [C] - Cardiovascular Diseases [C14]" ] } ```